AlphAIAlphAI — Financial news for AI agents
tradingview.comAUG 144 min read$HAE

HAE Stock Gains on Q1 Earnings & Revenue Beat, Fiscal '27 View Up

Haemonetics (HAE) reported fiscal Q1 2027 adjusted EPS of $1.14, up 3.6% and 6.5% above the Zacks consensus. Revenue rose 5.6% to $339.4 million, beating consensus. Management raised fiscal 2027 revenue guidance to 5-8% growth and organic growth to 4-7%.

Original reporting
tradingview.com
Published Aug 14, 2026, 3:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 15, 2026, 7:50 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
HAE Stock Gains on Q1 Earnings & Revenue Beat, Fiscal '27 View Up — source image
Source · tradingview.com
Decision brief

The 30-second read

$HAEBullishHigh
01

Why it matters

The key tradable catalyst is the combination of an earnings and revenue beat with a raised FY2027 revenue growth range, plus improved free cash flow and modest operating margin expansion.

02

Market read

Traders can reprice HAE’s FY2027 growth trajectory based on the raised revenue guidance and segment momentum, with margin and cash flow details informing quality of earnings.

03

What to watch

The article highlights Persona PLUS adoption and yield improvements, but does not quantify sustainability of the 5%+ yield benefit or the durability of collection trends into later quarters.

Relevance 9/10Novelty 9/10Timing: post-earnings, guidance update reported for fiscal 2027

Background

Haemonetics’ fiscal Q1 2027 results cover earnings, segment revenue growth (Apheresis, MedSurg), margin, and cash flow, followed by an updated full-year outlook.

Company-level read

Ticker impact

$HAEBullishHigh confidence
Context

Haemonetics reported fiscal Q1 2027 adjusted EPS of $1.14 and raised FY2027 revenue growth guidance to 5-8% from 4-7%.

Expected impact

Moderately positive bias for the next few sessions as traders reprice FY2027 revenue growth and organic growth assumptions.

Evidence & confidence

The article discloses a concrete earnings beat plus an explicit full-year guidance increase, alongside specific segment growth (Plasma, MedSurg) and free cash flow improvement.

Market effects

Sector

Signals continued demand strength in apheresis and MedSurg platforms, which can support sentiment for medical device peers with similar procedure-driven revenue models.

Regional

No specific regional demand shock is quantified beyond U.S. customer collections commentary.

Global

Limited global read-through because the article emphasizes U.S. collections and product adoption timelines rather than international regulatory or reimbursement changes.

Counterpoint

What could challenge this read

Guidance is raised, but gross margin is flat and COGS rose, so upside may be capped if cost pressures persist.

Key entities

  • company
    Haemonetics Corporation

    Subject of the article, reporting fiscal Q1 2027 results and raising fiscal 2027 revenue guidance.

  • product
    Persona PLUS

    Apheresis product rollout cited as ahead of schedule with early adopters reporting yield improvements.

Read at source← All news

Related articles

AUG 19
$HAEHighAI 8/10

Haemonetics reconnects with CSL in US plasma collection deal

Haemonetics (HAE) announced a new deal with CSL Plasma to supply its NexSys PCS platforms and apheresis kits for U.S. plasma collection centers. The contract, following FDA approval, does not have minimum purchase requirements. HAE shares rose 15% in after-hours trading, reaching $107. Analysts estimate potential revenue of $183M-$223M annually if CSL fully switches back, with a 6%-8% growth rate and 10%-20% pricing premium.

massdevice.com2 min
AUG 19
$HAEHigh

Haemonetics stock hits 52-week high at 106.64 USD

Haemonetics Corp (HAE) hit a 52-week high of $106.64, up 92.73% over a year. The medical tech firm's stock has surged 72.49% in six months and 14.57% in the past week. Q1 earnings beat estimates, with revenue at $339M. BTIG raised its price target to $96. HAE signed a supply deal with CSL Plasma.

investing.com2 min
AUG 18
$HAEMedAI 8/10

Up another 16% TODAY, see why this AI-picked medtech stock is now up +92%

Haemonetics Corporation (NYSE:HAE) rose 15.9% after announcing a supply agreement with CSL Plasma, adding to its 91.88% surge since being identified by InvestingPro's AI models. The company reported Q1 2027 revenue of $339.4M and adjusted EPS of $1.14, raising its full-year revenue growth outlook to 5-8%. InvestingPro's AI-powered stock picker has identified multiple stocks with significant gains, including Haemonetics, which was highlighted for its valuation, profitability, and growth potential

investing.com7 min
AUG 18
$HAEMed

Haemonetics stock surges 16% on CSL Plasma supply deal

Haemonetics (NYSE:HAE) shares rose 16.3% after it announced a non-exclusive U.S. supply agreement with CSL Plasma. Signed Aug. 14, 2026, it allows CSL to use Haemonetics NexSys PCS devices with Persona PLUS and buy related disposables, with no minimum purchase commitments. Haemonetics did not revise fiscal 2027 guidance and plans an update at its Q2 earnings call in Nov. 2026.

investing.com4 min
AUG 18
$HAEHighAI 9/10

Why is Haemonetics stock surging today?

Haemonetics (HAE) shares rose about 6.6% in pre-open after the company filed an 8-K for a non-exclusive supply agreement with CSL Plasma. The deal lets CSL deploy Haemonetics NexSys PCS devices with Persona PLUS and buy related disposables at U.S. centers. Investors also cited Haemonetics’ Aug. 6 Q1 FY2027 results: $339.4M revenue, $1.14 adjusted EPS, and raised FY2027 growth guidance to 5%–8%, plus analyst target increases.

investing.com4 min